SHSE:600276'
s Days Payable Range Over the Past 10 Years
Min: 146.87 Med: 167.79 Max: 210.43
Current: 183.56
During the past 13 years, Jiangsu Hengrui Pharmaceuticals Co's highest Days Payable was 210.43. The lowest was 146.87. And the median was 167.79.
SHSE:600276's Days Payable is ranked better than 82.43% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs SHSE:600276: 183.56
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hengrui Pharmaceuticals Co Days Payable Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hengrui Pharmaceuticals Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Days Payable falls into.
Jiangsu Hengrui Pharmaceuticals Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a Days Payable of 192.59 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. This is 15% above median its historical median of 167.79. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's Days Payable has ranged from 146.87 to 210.43. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #162 out of 922 companies in the Drug Manufacturers industry, placing it in the top 17.6%.
Is Jiangsu Hengrui Pharmaceuticals Co's Days Payable too high?
Jiangsu Hengrui Pharmaceuticals Co's current Days Payable of 192.59 is 15% above median its 10-year median of 167.79. Over the past 10 years, this metric has ranged from a low of 146.87 to a high of 210.43. The Drug Manufacturers industry median Days Payable is 90.61. Jiangsu Hengrui Pharmaceuticals Co's value of 192.59 is 112.5% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #162 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #162 out of 922 companies for Days Payable. This places Jiangsu Hengrui Pharmaceuticals Co in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.61. Jiangsu Hengrui Pharmaceuticals Co's value of 192.59 is 112.5% above this benchmark. Historically, Jiangsu Hengrui Pharmaceuticals Co's own Days Payable has ranged from 146.87 to 210.43 over the past decade. While the company's 10-year median is 167.79 vs. the industry median of 90.61, Jiangsu Hengrui Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current Days Payable of 192.59 is 112.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current Days Payable is 192.59, which is 15% above median its own 10-year median of 167.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Fairly Valued. The stock's GF Value™ is ¥60.64, compared to a current price of ¥55.61 — trading 8.3% below its estimated fair value. The current Days Payable is 192.59, which is 15% above median its 10-year median of 167.79 and 112.5% above the Drug Manufacturers industry median of 90.61. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current Days Payable is 192.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥55.61 is trading 8.3% below its estimated GF Value™ of ¥60.64.
GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Fairly Valued.
Key valuation signals for SHSE:600276:
Days Payable: 192.59 (15% above median its 10-year median of 167.79)
GF Value™: ¥60.64 vs. price of ¥55.61 (8.3% below fair value)
Industry Position: 112.5% above the Drug Manufacturers median (#162 of 922)
No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hengrui Pharmaceuticals Co Business Description
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
86GF Score
Get the complete analysis for SHSE:600276
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600276 has been successfully added to your 
